AnalystsInsight

Andrew Berens (Leerink Partners): Analyst Track Record and Price‑Target Accuracy

Andrew Berens is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Andrew covers, how Andrew’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Published Updated 2 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+1 new rating (stocks members‑only)

Key takeaways

  • Andrew Berens ranks among the top 50 healthcare analysts in Exent’s ranking, scored on a 7‑year backtest.
  • The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
  • Most‑covered stocks: INCY, IDYA, ARVN, CELC.
  • In the past year Andrew’s ratings were 94% Buy, 6% Hold and 0% Sell.

Andrew Berens’s track record at a glance

Andrew Berens of Leerink Partners ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Andrew’s exact rank, hit rate and live calls are for members.

MetricAndrew BerensAll analysts
Exent rank—
Price‑target hit rate52.4%
Calls up after 12 months64.0%
Median 12‑month return of calls+13.4%
Median days to hit target91 days
Stocks covered32—

How fast price targets were reached

Time to reach the targetAndrew Berens
Under 30 days25.8%
30–90 days18.2%
90–180 days22.7%
Over 180 days33.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Andrew Berens covers most

INCY · IDYA · ARVN · CELC · AGIO · AURA · CGEM · EXEL

In the past year Andrew’s ratings were 94% Buy, 6% Hold and 0% Sell.

Andrew Berens’s latest ratings

DateStockActionRatingPrice target
Sep 18, 2026BBOTRated: BuyBuy$25.00
Sep 10, 2026BBOTRated: BuyBuy$27.00
Aug 7, 2026CMPXReiterated: BuyBuy$7.00
Aug 6, 2026EXELDowngraded: HoldHold$52.00
Aug 3, 2026INCYReiterated: BuyBuy$155.00
Jul 7, 2026AGIOReiterated: BuyBuy$0.00
Jul 6, 2026PBLSInitiated Coverage: BuyBuy$40.00
Jun 2, 2026AURAReiterated: BuyBuy$0.00
Jun 2, 2026AURAReiteratedBuy—
May 15, 2026DMRAMaintainedBuy$51.00
May 15, 2026STRORatedBuy$43.00
May 15, 2026IMNMMaintainedBuy$33.00
  • Sep 18, 2026
    Stock
    BBOT
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $25.00
  • Sep 10, 2026
    Stock
    BBOT
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $27.00
  • Aug 7, 2026
    Stock
    CMPX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $7.00
  • Aug 6, 2026
    Stock
    EXEL
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $52.00
  • Aug 3, 2026
    Stock
    INCY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $155.00
  • Jul 7, 2026
    Stock
    AGIO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jul 6, 2026
    Stock
    PBLS
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $40.00
  • Jun 2, 2026
    Stock
    AURA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 2, 2026
    Stock
    AURA
    Action
    Reiterated
    Rating
    Buy
    Price target
    —
  • May 15, 2026
    Stock
    DMRA
    Action
    Maintained
    Rating
    Buy
    Price target
    $51.00
  • May 15, 2026
    Stock
    STRO
    Action
    Rated
    Rating
    Buy
    Price target
    $43.00
  • May 15, 2026
    Stock
    IMNM
    Action
    Maintained
    Rating
    Buy
    Price target
    $33.00

Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Andrew Berens’s full record and latest ratings, without the 30‑day delay.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Andrew Berens ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Andrew Berens’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 52.4% of the time.

Andrew Berens (Leerink Partners) covers 32 stocks, mostly in healthcare. The most frequently rated are INCY, IDYA, ARVN, CELC, AGIO.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.